Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.

By L. Tavazzi, A. Maggioni, R. Marchioli, S. Barlera, M. Franzosi, R. Latini, Donata Lucci, Gianluigi Nicolosi, Maurizio Porcu, Gianni Tognoni. The Lancet, 2008

1,101 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/79550a64cdc0f936a659fc9d367bc257ec245b79

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. D. Lloyd‐Jones
2. Daniel Levy

In Surgery

1. D. Lloyd‐Jones
2. J. Liao
3. R. Eckel
4. Ulrich Laufs

Citations in the corpus

• 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, neutral): “However, 2 large RCTs have demonstrated that rosuvastatin has neutral effects on long-term outcomes in patients with chronic HFrEF when added to standard GDMT.(537,538) At present, statin therapy should not be prescribed primarily for the treatment of HF to improve clinical outcomes.”
• Pleiotropic Effects of Statins on the Cardiovascular System (2017, background): “However, both the large randomized GISSIHF (Effect of Rosuvastatin in Patients With Chronic Heart Failure) and CORONA (Rosuvastatin in Older Patients With Systolic Heart Failure) trials did not show any benefit for either death or the composite end point.(161,162) Although there are questions about ”
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, neutral): “Both for GDMT and other recommended drug treatment regimens, the reader is advised to confirm dosages with product insert material and to evaluate carefully for contraindications and drug-drug interactions.”
• ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011, neutral): “Observational studies are subject to confounding, and treatment with statins should not be started in patients with moderate to severe HF [New York Heart Association (NYHA) classification III– IV].36,39 However, there is no evidence for harm in patients on statin treatment after the occurrence of HF”
• Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. (2014, background): “events in 2 RCTs for each condition (86-89), there was insufficient information on which to base recommendations for or against statin treatment.”